Arrakis Therapeutics

OverviewSuggest Edit

Arrakis Therapeutics is a biopharmaceutical company which offers a drug discovery platform intended to target RNA. The Company develops an internal product pipeline of RNA-targeted small molecules focused on neurology, oncology, and rare genetic disorders. It offers scientific platforms, such as TRYST, MARS, PEARL-Seq, to identify tractable RNA targets, design drug molecules, and select candidates for clinical development. 
TypePrivate
Founded2015
HQWaltham, US
Websitearrakistx.com

Latest Updates

Employees (est.) (Sep 2019)45

Key People/Management at Arrakis Therapeutics

Michael Gilman

Michael Gilman

PhD, Chief Executive Officer
Jennifer C. Petter

Jennifer C. Petter

PhD, Founder and Chief Scientific Officer
Daniel E. Koerwer

Daniel E. Koerwer

Chief Business Officer
James Barsoum

James Barsoum

PhD, Senior Vice President, Research
Heather Lounsbury

Heather Lounsbury

Vice President, Business & Technical Operations
Gnanasambandam Kumaravel Kumar

Gnanasambandam Kumaravel Kumar

PhD, Vice President of Chemistry
Show more

Arrakis Therapeutics Office Locations

Arrakis Therapeutics has an office in Waltham
Waltham, US (HQ)
Waltham, MA 02451, USA
Waltham, US (HQ)
35 Gatehouse Dr
Show all (2)

Arrakis Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2015

Arrakis Therapeutics total Funding

$113 m

Arrakis Therapeutics latest funding size

$75 m

Time since last funding

5 months ago

Arrakis Therapeutics investors

Arrakis Therapeutics's latest funding round in April 2019 was reported to be $75 m. In total, Arrakis Therapeutics has raised $113 m
Show all financial metrics

Arrakis Therapeutics Online and Social Media Presence

Embed Graph

Arrakis Therapeutics News and Updates

Arrakis Therapeutics Announces $75 Million Series B Financing To Advance a New Class of Small-Molecule Medicines Targeting RNA

The Life Sciences team advised Arrakis Therapeutics, a biopharmaceutical company pioneering the discovery of a new class of small-molecule medicines that directly target RNA, on its $75 million Series B financing.read more

Arrakis Therapeutics Blogs

Arrakis achieves escape velocity

When last we spoke (here and here), Arrakis had just achieved liftoff with a $38M Series A financing in February 2017, and we were awash in fascinating and, in some cases, vexing questions. Two of my own questions that stand out upon rereading those posts from two years ago are: Is medicinal chemist…

Data‐driven Guideposts for Targeting RNA

RNA’s fundamental role in biology has made it a burgeoning area for technology development and application, including as an intervention point for drug development. Virtually every step in the expression of a human gene involves RNA, from transcription through processing, localization and, ultimatel…

Arrakis Therapeutics Frequently Asked Questions

  • When was Arrakis Therapeutics founded?

    Arrakis Therapeutics was founded in 2015.

  • Who are Arrakis Therapeutics key executives?

    Arrakis Therapeutics's key executives are Michael Gilman, Jennifer C. Petter and Daniel E. Koerwer.

  • How many employees does Arrakis Therapeutics have?

    Arrakis Therapeutics has 45 employees.

  • Who are Arrakis Therapeutics competitors?

    Competitors of Arrakis Therapeutics include AVEO Pharmaceuticals, Clovis Oncology and Northwest Biotherapeutics.

  • Where is Arrakis Therapeutics headquarters?

    Arrakis Therapeutics headquarters is located at Waltham, MA 02451, USA, Waltham.

  • Where are Arrakis Therapeutics offices?

    Arrakis Therapeutics has an office in Waltham.

  • How many offices does Arrakis Therapeutics have?

    Arrakis Therapeutics has 2 offices.